公开(公告)号：WO2019067706A4

公开(公告)日：2019-04-04

申请号：PCT/US2018/053099

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  TU, Naxin ,  MEAGHER, Karolina ,  MACDONALD, Lynn ,  MURPHY, Andrew ,  STEVENS, Sean

IPC: A01K67/027 ,  C07K14/47

Abstract: Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals.

公开(公告)号：WO2021045836A1

公开(公告)日：2021-03-11

申请号：PCT/US2020/039707

申请日：2020-06-25

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： BABB, Robert ,  BAUM, Alina ,  CHEN, Gang ,  GERSON, Cindy ,  HANSEN, Johanna ,  HUANG, Tammy ,  KYRATSOUS, Christos ,  LEE, Wen-Yi ,  MALBEC, Marine ,  MURPHY, Andrew ,  OLSON, William ,  STAHL, Neil ,  YANCOPOULOS, George, D.

IPC: A61K39/215 ,  A61K39/395 ,  A61K45/06 ,  C07K16/10

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections). The present disclosure provides neutralizing human antigen-binding proteins that specifically bind to SARS-CoV-2-S, for example, antibodies or antigen-binding fragments thereof.

公开(公告)号：WO2021026409A1

公开(公告)日：2021-02-11

申请号：PCT/US2020/045309

申请日：2020-08-07

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： ZHANG, Tong ,  PYLES, Erica ,  ROSCONI, Michael ,  LIU, Nina ,  PATEL, Supriya ,  SMITH, Eric ,  MURPHY, Andrew ,  LIN, Chiayang ,  DAVIS, Samuel

IPC: C07K16/24 ,  C07K16/28 ,  C07K16/46

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

公开(公告)号：WO2020018511A1

公开(公告)日：2020-01-23

申请号：PCT/US2019/041964

申请日：2019-07-16

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MURPHY, Andrew ,  MUJICA, Alexander O. ,  LAI, Ka-Man Venus ,  SOKOL, Haxhinasto ,  ZARUHI, Hovhannisyan

IPC: A01K67/027 ,  C07K14/54 ,  C07K14/715

Abstract: This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36, and ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.

公开(公告)号：WO2023086812A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079530

申请日：2022-11-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SHEN, Yang ,  WANG, Bei ,  AVVARU, Naga Suhasini ,  LIN, Chia-Yang ,  MURPHY, Andrew ,  HERMANN, Aynur ,  KIM, Jee H.

IPC: C07K16/28 ,  C07K14/705

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

公开(公告)号：WO2023283134A1

公开(公告)日：2023-01-12

申请号：PCT/US2022/035968

申请日：2022-07-01

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MURPHY, Andrew ,  KYRATSOUS, Christos ,  BAUM, Alina ,  PETRO, Christopher

IPC: C07K16/10 ,  A61K39/215 ,  A61P31/14

Abstract: Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.

公开(公告)号：WO2015127158A1

公开(公告)日：2015-08-27

申请号：PCT/US2015/016737

申请日：2015-02-20

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： GROMADA, Jesper ,  SMITH, Eric ,  MURPHY, Andrew ,  PAPADOPOULOS, Nicholas ,  MARTIN, Joel ,  YANCOPOULOS, George ,  MACDONALD, Douglas ,  BUCKLER, David

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/02 ,  C07K16/30

CPC classification number: C07K16/32 ,  A61K39/39558 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2869 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/75

Abstract: The present invention provides, inter alia, a method for cell-specific modulation of a target antigen. The method comprises contacting a target cell having the target antigen on the surface of the target cell with: (a) first multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C1), (ii) a target antigen binding domain (T1); and (b) a second multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C2), (ii) a target antigen binding domain (T2); wherein C1 and C2 interact with the same cell-specific antigen, and the cell-specific antigen and the target antigen are on the same target cell. Pharmaceutical compositions and kits thereof are also included in the present invention.

Abstract translation: 本发明尤其提供了靶抗原的细胞特异性调节方法。 该方法包括使靶细胞表面上具有目标抗原的靶细胞与（a）第一多特异性抗原结合多肽包含：（i）细胞特异性抗原结合结构域（C1），（ii） 靶抗原结合结构域（T1）; （b）第二多特异性抗原结合多肽，其包含：（i）细胞特异性抗原结合结构域（C2），（ii）靶抗原结合结构域（T2）; 其中C1和C2与相同的细胞特异性抗原相互作用，细胞特异性抗原和靶抗原位于相同的靶细胞上。 药物组合物及其试剂盒也包括在本发明中。

公开(公告)号：WO2019067706A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/053099

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  TU, Naxin ,  MEAGHER, Karolina ,  MACDONALD, Lynn ,  MURPHY, Andrew ,  STEVENS, Sean

IPC: A01K67/027 ,  C07K14/47

Abstract: Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals.

公开(公告)号：WO2019067682A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/053064

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  MURPHY, Andrew ,  MEAGHER, Karolina ,  MASON, Peter

IPC: C07K16/12 ,  C07K16/18 ,  A61K39/00

Abstract: According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10nM or less, and/or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of a Staphylococcus species is desired and/or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating a staphylococcus infection that occurs as a result of a surgical procedure.

公开(公告)号：WO2018190970A1

公开(公告)日：2018-10-18

申请号：PCT/US2018/021109

申请日：2018-03-06

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： STEVIS, Panayiotis ,  ESOPI, David ,  GROMADA, Jesper ,  HALLER, Jorge ,  LIU, Yashu ,  MURPHY, Andrew ,  OLSON, William

IPC: C12Q1/32

Abstract: Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.